P-ISSN 2587-2400 | E-ISSN 2587-196X
Ejmo Kapak
EJMO Volume : 6 Issue : 4 Year : 2022
EJMO. 2022; 6(4): 299-306 | DOI: 10.14744/ejmo.2023.79236

Evaluation of MicroRNA Expressions in Ovarian Cancer

Husnu Tore Yavuzsen1, Zekiye Sultan Altun2, Gulden Diniz3, Duygu Ayaz4, Sevil Sayhan4, Ilker Cakir5, Bahadir Saatli6, Tugba Yavuzsen7, Safiye Aktas7
1Department of Gynecology and Obstetrics, Izmir Buca Maternity and Children Hospital, Izmir Democracy University, Izmir, Türkiye Department of Gynecology and Obstetrics, Izmir Buca Maternity and Children Hospital, Izmir Democracy University, Izmir, Türkiye, 2Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Türkiye, 3Department of Medical Pathology, Medical Faculty, Izmir Democracy University, Izmir Türkiye, 4Department of Pathology, Tepecik Training and Research Hospital, Health Sciences University, Izmir, Türkiye, 5Department of Gynecology and Obstetrics, Izmir Buca Maternity and Children Hospital, Izmir Democracy University, Izmir, Türkiye, 6Department of Gynecology and Obstetrics, Medical Faculty, Dokuz Eylul University, Izmir, Türkiye, 7Department of Internal Medicine, Division of Medical Oncology, Medical Faculty, Dokuz Eylul University, Izmir, Türkiye,

Objectives: The present study aims to evaluate the relationship between microribonucleic acid (miRNA) and target gene expressions with clinical and histopathological data in ovarian cancer. Methods: We evaluated 96 archival samples of paraffin-embedded tissue. Some potentially significant miRNA and target gene expressions were evaluated in different histopathological characteristics. These were quantified using realtime–polymerase chain reaction (RT–PCR) in tumor and normal tissue. In miRNA expressions, twofold changes are accepted as significant. Results: According to histopathological groups, 38 (39.6%) were endometroid adenocarcinoma, 11 (11.5%) were borderline serous, 29 (30.2%) were serous, and 18 (18.8%) were mucinous carcinoma. When evaluated according to their stages, 26 (27.1%) patients were stage 1A/1B. A relationship was found between miR200a and miR200c and histopathologic groups, between miR141 and estrogen receptors, between CXCL1 and survival status, and between KEAP1 and ki67. Additionally, miR200a in endometrial and miR200c in mucinous adenocarcinoma were overexpressed. When the relationship between all miRNAs and histopathological groups was evaluated, a significant change was found only in miR200c expression. It was significantly higher in serous than endometrial tumors and significantly higher in mucinous than endometroid tumors. Conclusion: These suggested that miR200a and 200c expressions might be useful for the evaluation of histopathological subgroups of ovarian cancer. Keywords: Biomarkers, Ovarian Cancer, MicroRNA


Cite This Article

Yavuzsen H, Altun Z, Diniz G, Ayaz D, Sayhan S, Cakir I, et al. Evaluation of MicroRNA Expressions in Ovarian Cancer. EJMO. 2022; 6(4): 299-306

Corresponding Author: Husnu Tore Yavuzsen

Full Text PDF PDF Download
EJMO & EJMO